Showing results (791-800 of 1,188) with videos related to
Sort By:
Pageof 119
Leukemia|June 13, 2022
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemiaYue Wei, Rashmi Kanagal-Shamanna, Hong Zheng, et al.Cancer|April 24, 2018
Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panelsCourtney D DiNardo, Mark J Routbort, Sarah A Bannon, et al.American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.JCO Precision Oncology|October 31, 2019
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial IntelligenceAziz Nazha, Mikkael A Sekeres, Rafael Bejar, et al.American Journal of Hematology|July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, William G Wierda, William Plunkett, et al.Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.Leukemia Research|November 9, 2015
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesTalha Badar, Keyur P Patel, Philip A Thompson, et al.Cancer|January 31, 2020
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemiaLucia Masarova, Jorge E Cortes, Keyur P Patel, et al.Pageof 119